KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Accounts Payables (2018 - 2026)

Takeda Pharmaceutical has reported Accounts Payables over the past 9 years, most recently at $3.1 billion for Q1 2026.

  • For Q1 2026, Accounts Payables rose 0.52% year-over-year to $3.1 billion; the TTM value through Mar 2026 reached $3.1 billion, up 0.52%, while the annual FY2026 figure was $3.3 billion, 4.56% up from the prior year.
  • Accounts Payables was $3.1 billion for Q1 2026 at Takeda Pharmaceutical, up from $3.1 billion in the prior quarter.
  • Across five years, Accounts Payables topped out at $4.9 billion in Q1 2023 and bottomed at $3.1 billion in Q1 2025.
  • The 5-year median for Accounts Payables is $3.7 billion (2024), against an average of $3.9 billion.
  • Year-over-year, Accounts Payables surged 36.76% in 2022 and then dropped 24.73% in 2024.
  • Over 5 years, Accounts Payables stood at $4.4 billion in 2022, then grew by 10.48% to $4.9 billion in 2023, then dropped by 24.73% to $3.7 billion in 2024, then dropped by 15.63% to $3.1 billion in 2025, then rose by 0.52% to $3.1 billion in 2026.
  • The last three reported values for Accounts Payables were $3.1 billion (Q1 2026), $3.1 billion (Q1 2025), and $3.7 billion (Q1 2024) per Business Quant data.